石藥集團(01093.HK):安複利克®列入國家醫保目錄
格隆匯12月3日丨石藥集團(01093.HK)宣佈,集團的安複利克®("注射用兩性黴素B膽固醇硫酸酯複合物(50mg)")被列入國家醫保藥品目錄(2021年)乙類範圍。該產品於2021年3月獲頒藥品註冊批件,適用於患有深部真菌感染的患者、因腎損傷或藥物毒性而不能使用有效劑量的兩性黴素B的患者或已經接受過兩性黴素B治療無效的患者均可使用。
兩性黴素B屬於多烯類抗生素,是抗菌活性最強、抗菌譜最廣的侵襲性真菌病治療藥物之一。與目前國內臨牀中使用的注射用兩性黴素B相比,安複利克®具備獨特的藥物攝取及釋放機制,顯著改善兩性黴素B的腎毒性、低鉀血癥等不良反應;並有效增加給藥劑量,從而提高治療指數。該產品可促使更多患者得到治療和治癒的機會,獲得更好的生存預後。
董事會相信,安複利克®被納入國家醫保目錄證明其臨牀價值、創新程度和對患者的益處等方面受到認可,並可提高該產品的可負擔性和可及性,為其長期增長注入動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.